ANALYTICS, QC:

• Espel Grekopoulos J: Construction and Validation of Quantification Methods for Determining the Cannabidiol Content in Liquid Pharma-Grade Formulations by Means of Near-Infrared Spectroscopy and Partial Least Squares Regression. Med Cannabis Cannabinoids 2019, 2(1) ↓ PDF
• Hazekamp A.: The Trouble with CBD Oil. Med Cannabis Cannabinoids 2018, 1(1) ↓ PDF

ANXIETY:

• Wright M et al: Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence. CCR 2020, 5(3) ↓ PDF
• O’Sullivan SE et al: Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders? CCR 2021; 6(1): 7 ↓ PDF
• Wright M et al: Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence. CCR 2020; 5(3): 191 ↓ PDF

BOTANICS:

• Jin D et al: Identification of phenotypic characteristics in three chemotype categories in the genus Cannabis. HortScience Febr 2021 ↓ PDF
• Ren G et al: Large-scale whole-genome resequencing unravels the domestication history of Cannabis sativa. Sci Adv 2021, 7 ↓ Link

CORONA, COVID:

• van Breemen RB et al: Cannabinoids block cellular entry of SARS-CoV-2 and the emerging variants. J Nat Prod. 2022 ↓ PDF
• Nguyen LC et al: Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv 2022; 8 (Jan.) ↓ PDF

DEMENTIA:

• Broers B, Patà Z, Mina A, Wampfler J, de Saussure C, Pautex S: Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva. Med Cannabis Cannabinoids 2019, 2(1) ↓ PDF

ENTOURAGE EFFECT:

• Hanuš LO, Hod Y: Terpenes/Terpenoids in Cannabis: Are They Important? MCA 2020, 3(1) ↓ PDF
• Santiago M et al: Absence of Entourage: Terpenoids Commonly Found In Cannabis sativa Do Not Modulate the Functional Activity of delta-9-THC at Human CB1 and CB2 Receptors. CCR 2019; 4(3) ↓ PDF

EXAMINATION WORK:

• Wittwer B, Brändle R, Boqolli E: Hanf – Von der Droge zum Arzneimittel. Abschlussarbeit Berufs- und Weiterbildungszentrum Wil-Uzwil 2021 ↓ PDF

EPILEPSY:

• Zafar RR, Schlag AK, Nutt DJ: Ending the pain of children with severe epilepsy? An audit of the impact of medical cannabis in 10 patients. Drug Science, Policy and Law 2020; 6: 1-6 ↓ PDF

FORMULATIONS, GALENICS:

• Palrasu M et al: Perspectives on Challenges in Cannabis Drug Delivery Systems: Where Are We? Med Cannabis Cannabinoids 2022; 5: 102-119 ↓ PDF

HANDBOOKS:

• Ahmad S, Hill KP: Medical Marijuana: A Clinical Handbook. Wolters Kluwer 2020

GYNECOLOGY:

• Luschnig P, Schicho R: Cannabinoids in Gynecological Disease. Med Cannabis Cannabinoids 2019, 2(1) ↓ PDF

IBD:

• van Orten-Luiten ACB et al: Effects of Cannabidiol Chewing Gum on Perceived Painand Well-Being of Irritable Bowel Syndrome Patients:A Placebo-Controlled Crossover Exploratory InterventionStudy with Symptom-Driven Dosing. CCR 2021 ↓ PDF

INFLAMMATION:

• Ma H et al: A Network Pharmacology Approach to Identify Potential Molecular Targets for Cannabidiol’s Anti-Inflammatory Activity. CCR 2021 ↓ PDF

LAW:

• Veit M & Ziegler AS: CBD-Produkte: Verkehrsfähigkeit und Abgrenzung zu Medizinal-Cannabis. Pharm Ind 2022 ↓ PDF

OPIOID CRISIS:

• Piomelli D: Cannabis and the opioid crisis. CCR 2018 ↓ PDF

PAIN:

• Gazendam A et al: Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis. CCR 2020, 5(4) ↓ PDF
• van Orten-Luiten ACB et al: Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. CCR 2021 ↓ PDF
• Dunn KE et al: Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. Neuropsychopharmacol 2021 ↓ PDF
• Zylla DM et al: A randomized trial of medical cannabis with patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Supp Care Cancer 2021 ↓ PDF
• Busse JW et al: Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ 2021;374:n2040 ↓ PDF
• Gazendam A et al: Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis. CCR 2020; 5(4): 290 ↓ PDF
• Gilman JM et al: Effect of medical marijuana card membership on pain, insomnia and affective disorder symptoms in adults – A randomized clinical trial. JAMA Network Open 2022 ↓ PDF
• Zieglgänsberger W et al: Chronic pain and the endocannabinoid system: Smart lipids – A novel therapeutic option? Med Cannabis Cannabinoids 2022; 5: 61-75 ↓ PDF

PHARMAKOKINETICS:

• Kocis PT, Vrana KE: Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions. Med Cannabis Cannabinoids 2020, 3(1) ↓ PDF
• Meyer P. · Langos M. · Brenneisen R.: Human Pharmacokinetics and Adverse Effects of Pulmonary and Intravenous THC-CBD Formulations. Med Cannabis Cannabinoids 2018, 1(1) ↓ PDF
• Millar SA et al: Towards Better Delivery of Cannabidiol (CBD). Pharmaceuticals 2020, 13: 219 ↓ PDF
• Lorenzl S et al: A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery. Med Cannabis Cannabinoids 2022; 5: 9-19 ↓ PDF

PLACEBO EFFECT:

• Gertsch J.: The Intricate Influence of the Placebo Effect on Medical Cannabis and Cannabinoids. Med Cannabis Cannabinoids 2018, 1(1) ↓ PDF

REVIEWS:

• Bilbao A & Spanagel R: Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med 2022; 20:259 ↓ PDF
• Brusa P et al (eds.): Medicinal Cannabis: Evolution of Therapeutic Use, Future Approaches and Other Implications. Lausanne: Frontiers Media SA; 2022; doi: 10.3389/978-2-83250-163-4 ↓ PDF
• Diverse Autoren, Psychiatrie + Neurologie 2023; 5; 2-38 ↓ PDF
  • Vaney C. & Brenneisen R.: Editorial- Vom Paria zur verordneten Medizin
  • Vaney C. & Fankhauser M.: Etwas Medizingeschichte zum Thema Cannabis
  • Vaney C. & Eigenmann D.: Cannabis in der Behandlung der Spastik und anderer Symptome der Multiplen Sklerose
  • Agosti R., Lamers G., Czell D., Gertsch G. & Kupferberg A.: Cannabis in der akuten und prophylaktischen Behandlung der Migräne?
  • Broers B. & Bianchi F.: Cannabinoide und Demenz
  • Hoederath P. & Vaney C.: Cannabis bei chronischen Schmerzen – mehr als eine Option?
  • Goldman B.: Erleichterter Zugang zu Cannabisarzneimitteln: Was bedeutet das für Verschreibende und Medizinfachpersonen?
  • Baltes-Flückiger L. & Walter M: Regulierte Cannabisabgabe zu Genusszwecken in der Schweiz: Das Basler Pilotprojekt WEED CARERauschkonsum und medizinische Anwendung
• Pisanti S. et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics 2017; 175: 133-150 ↓ PDF

SLEEP:

• Walsh JH et al: Treating Insomnia Symptoms with Medicinal Cannabis: A Randomized, Cross-Over Trial of the Efficacy of a Cannabinoid Medicine Compared with Placebo. Sleep 2021 ↓ PDF

TOURETTE SYNDROME:

• Szejko N, Jakubovski E, Fremer C, Müller-Vahl KR: Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome. Med Cannabis Cannabinoids 2019, 2(1) ↓ PDF
• Müller-Vahl K: Case in Context: Tourette Syndrome. CCR March 2021 ↓ PDF

VARIOUS TOPICS:

• IACM-Informationen (mtl.) → Link
• Kruger DJ: Assessing Health Care Providers’ Knowledge of Medical Cannabis. CCR 2021 ↓ PDF
• Scharf R: Cannabis in der Hausarztpraxis. Innere Medizin 2/2022, Bericht FomF Innere Medizin Update Refresher 2021 ↓ PDF